Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.66 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.61 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | NLN | Q9BYT8 | 1/20 | 0.50 |
| ▸ | DPP8 | Q6V1X1 | 5/20 | 0.49 |
| ▸ | DPP7 | Q9UHL4 | 4/20 | 0.49 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.45 |
| ▸ | UBE2N | P61088 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4770838 | 0.85 | DPP4 (0.51) | DPP4HDAC8HDAC3HDAC1HDAC2 | |
| SCHEMBL2700469 | 0.78 | ALPI (0.54) | DPP4 | |
| SCHEMBL29440959 | 0.78 | ALPI (0.54) | DPP4 | |
| SCHEMBL45382 | 0.78 | ALPI (0.54) | DPP4 | |
| SCHEMBL4393088 | 0.78 | ALPI (0.54) | DPP4 | |
| SCHEMBL29574121 | 0.78 | ALPI (0.54) | DPP4 | |
| SCHEMBL12936626 | 0.77 | MTNR1A (0.54) | DPP4 | |
| SCHEMBL5295968 | 0.77 | TSHR (0.53) | DPP4RAD52UBE2N | |
| SCHEMBL5295982 | 0.77 | TSHR (0.53) | DPP4RAD52UBE2N | |
| SCHEMBL8242087 | 0.77 | HDAC8 (1.00) | DPP4HDAC8HDAC3HDAC1HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1996550-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | Novartis AG (CH) | 2008-12-03 | — | — | EP | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | claimed |
| WO-2007038459-A2 | CARBOXYAMINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF HDAC DEPENDENT DISEASES | NOVARTIS AG (CH) | 2007-04-05 | — | — | WO | claimed |
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | NOVARTIS AG | 2008-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255149-A1 | Carboxyamine Compounds and Methods of Use Thereof | HNMT, HDAC5, HDAC4 | DPP4 616/4885HDAC8 16/4885HDAC3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.